The Trump administration adds nine drugmakers to its Most Favored Nation pricing program, GSK advances its dual-antigen mRNA ...

Carelon Research's Mark Cziraky on why the industry's need for deeper, linked data is driving a shift toward trusted research environments.

Simcere Zaiming has licensed its first-in-class tri-specific CD79a/CD19/CD3 T-cell engager Sim0660 to Roche for up to $1.53 ...

Carelon Research's Mark Cziraky on why the industry's need for deeper, linked data is driving a shift toward trusted research ...

In March of this year, ACTO co-founder and CEO Parth Khanna wrote a piece for Pharmaceutical Executive discussing an area where he sees AI making a major impact. According to him, digital health ...

There is a myth in our industry that when an RBQM implementation fails to deliver the cause must be technical. It was the ...

Nate Hill, co-founder & CEO of Strive Pharmacy, argues that a Category one designation for peptides would give physicians a trusted, regulated channel they currently lack. Nate Hill, Co-Founder & CEO ...